Journal of clinical lipidology · 2026
Association between lipoprotein(a) and structural degeneration of bioprosthetic aortic valves: A systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Echeverría-Ortegón Ermilo, Torres-Chávez Mario César, Tejeda Alfredo Pérez-Tagle, Caballero Paulina, Pastor-Cervantes Juan
Аннотация
BACKGROUND: Structural valve degeneration (SVD) remains a major limitation of bioprosthetic aortic valves (bAVs). Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor implicated in native aortic valve calcification, but its role in bioprosthetic valve degeneration remains incompletely understood.
OBJECTIVE: To systematically evaluate the association between elevated Lp(a) levels and structural degeneration of bAVs.
METHODS: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EBSCOhost, and Cochrane Library databases were searched for studies evaluating Lp(a) and structural degeneration of bAVs in patients undergoing surgical or transcatheter aortic valve replacement. Random-effects models were used to pool effect estimates. Cross-sectional outcomes were summarized using odds ratios (ORs), and longitudinal outcomes were pooled using hazard ratios (HRs), both with 95% CIs.
RESULTS: Five observational cohort studies, including 1227 patients, were included. In cross-sectional analyses (2 studies), elevated Lp(a) levels were significantly associated with SVD (OR 2.09, 95% CI 1.02-4.28; I² = 0%). In longitudinal analyses (3 studies), elevated Lp(a) was associated with a higher risk of incident SVD or valve-related reintervention (HR 3.49, 95% CI 2.18-5.59; I² = 0%).
CONCLUSION: Elevated Lp(a) levels are associated with an increased risk of structural degeneration in bAVs. Lp(a) may represent a useful biomarker for identifying patients at higher risk of valve deterioration and may have implications for surveillance strategies and emerging Lp(a)-lowering therapies.
OBJECTIVE: To systematically evaluate the association between elevated Lp(a) levels and structural degeneration of bAVs.
METHODS: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EBSCOhost, and Cochrane Library databases were searched for studies evaluating Lp(a) and structural degeneration of bAVs in patients undergoing surgical or transcatheter aortic valve replacement. Random-effects models were used to pool effect estimates. Cross-sectional outcomes were summarized using odds ratios (ORs), and longitudinal outcomes were pooled using hazard ratios (HRs), both with 95% CIs.
RESULTS: Five observational cohort studies, including 1227 patients, were included. In cross-sectional analyses (2 studies), elevated Lp(a) levels were significantly associated with SVD (OR 2.09, 95% CI 1.02-4.28; I² = 0%). In longitudinal analyses (3 studies), elevated Lp(a) was associated with a higher risk of incident SVD or valve-related reintervention (HR 3.49, 95% CI 2.18-5.59; I² = 0%).
CONCLUSION: Elevated Lp(a) levels are associated with an increased risk of structural degeneration in bAVs. Lp(a) may represent a useful biomarker for identifying patients at higher risk of valve deterioration and may have implications for surveillance strategies and emerging Lp(a)-lowering therapies.